Frontier Dispatch: Deep Tech Conversations
The conversation covers the development of novel neurotherapeutics by Xylo, the motivation and impact behind the work, Xylo's unfair advantage, Zoma Labs' continuous glucose monitoring, their unfair advantage, and Currus Biologics' cell therapy for solid tumors. Hosted by Elaine Stead.
4 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de Frontier Dispatch: Deep Tech Conversations community!